Britain’s number two drugmaker — one of the biggest international pharma firms in China, with 45,000 staff — falsely recorded improper payments in China and Russia as bona fide business expenses, the US Securities and Exchange Commission said. Some bribery allegations go back as far as 2005, with AstraZeneca said to have made “improper payments of gifts, conference support, travel, cash and other benefits” mainly to Chinese and Russian state medical workers “to reward or influence” their purchases of its drugs.